Skip to main content

Advertisement

SpringerLink
Log in

Immunotoxins for the Treatment of B-Cell Lymphomas

  • Minireview
  • Published:
Molecular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Harris NL, Jaffe ES, Stein H, et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361–1392.

    PubMed  CAS  Google Scholar 

  2. Rosenberg SA. (1994) Classification of lymphoid neoplasms. Blood 84: 1359–1363.

    PubMed  CAS  Google Scholar 

  3. Hiddemann W, Longo DL, Coiffier B, et al. (1996) Lymphoma classification—The gap between biology and clinical management is closing. Blood 88: 4085–4089.

    PubMed  CAS  Google Scholar 

  4. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA. (1991) An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res. 51: 6236–6242.

    PubMed  CAS  Google Scholar 

  5. Thorpe PE, Detre SI, Foxwell BMJ, et al. (1985) Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem. 147: 197–206.

    Article  CAS  PubMed  Google Scholar 

  6. Thorpe PE, Wallace PM, Knowles PP, et al. (1988) Improved anti-tumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res. 48: 6396–6403.

    PubMed  CAS  Google Scholar 

  7. Ghetie M, May RD, Till M, et al. (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48: 2610–2617.

    PubMed  CAS  Google Scholar 

  8. Shen G, Li J, Ghetie M, et al. (1988) Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer 42: 792–797.

    Article  CAS  PubMed  Google Scholar 

  9. Irvin JD, Uckun FM. (1992) Pokeweed antiviral protein-ribosome inactivation and therapeutic applications. Pharmacol. Ther. 55: 279–302.

    Article  CAS  PubMed  Google Scholar 

  10. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63: 1424–1433.

    PubMed  CAS  Google Scholar 

  11. Campana D, Janossy G, Bofill M, et al. (1985) Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J. Immunol. 134: 1524–1529.

    PubMed  CAS  Google Scholar 

  12. Dörken B, Moldenhauer G, Schwartz R, Pezzutto A, Hammerling G. (1983) B cell differentiation antigens identified by monoclonal antibodies (HD6, HD28, HD37, HD39). Immunobiology 165: 253–254.

    Google Scholar 

  13. Ghetie V, Thorpe PE, Ghetie M, Knowles P, Uhr JW, Vitetta ES. (1991) The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J. Immunol. Methods 142: 223–230.

    Article  CAS  PubMed  Google Scholar 

  14. Ghetie V, Ghetie M, Uhr JW, Vitetta ES. (1988) Large scale preparation of immunotoxins constructed with the Fab’ fragment of IgGl murine monoclonal antibodies and chemically deglycosylated ricin A chain. J. Immunol. Methods 112: 267–277.

    Article  CAS  PubMed  Google Scholar 

  15. Fulton RJ, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES. (1986) Production of ricin A1, A2, and B chains and characterization of their toxicity. J. Biol. Chem. 261: 5314–5319.

    PubMed  CAS  Google Scholar 

  16. Knowles PP, Thorpe PE. (1987) Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem. 160: 440–443.

    Article  CAS  PubMed  Google Scholar 

  17. Endo Y, Mitsui K, Motizuki M, Tsurugi K. (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 262: 5908–5912.

    PubMed  CAS  Google Scholar 

  18. Bjorn MJ, Ring D, Frankel A. (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 45: 1214–1221.

    PubMed  CAS  Google Scholar 

  19. Weiner LM, O’Dwyer J, Kitson J, et al. (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-re-combinant ricin A chain immunoconjugate. Cancer Res. 49: 4062–4067.

    PubMed  CAS  Google Scholar 

  20. Vanhorssen PJ, Preijers FWMB, Vanoosterhout YVJM, Dewitte T. (1996) Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in Nude mice. Int. J. Cancer 68: 378–383.

    Article  CAS  Google Scholar 

  21. Blakely DC, Watson GJ, Knowles PP, Thorpe PE. (1987) Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 47: 947–952.

    Google Scholar 

  22. Nadler LM, Anderson KC, Marti G, et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 131: 244–250.

    PubMed  CAS  Google Scholar 

  23. Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM. (1991) Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD 19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. Methods 136: 221–237.

    Article  CAS  PubMed  Google Scholar 

  24. Uckun FM. (1993) Immunotoxins for the treatment of leukemia. Br. J. Haematol. 85: 435–438.

    Article  CAS  PubMed  Google Scholar 

  25. Mansfield E, Pastan I, FitzGerald DJ. (1996) Characterization of RFB4—Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug. Chem. 7: 557–563.

    Article  CAS  PubMed  Google Scholar 

  26. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. (1990) Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer 45: 481–485.

    Article  CAS  PubMed  Google Scholar 

  27. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. (1994) Anti-CD 19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83: 1329–1336.

    PubMed  CAS  Google Scholar 

  28. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. (1991) Antitumor activity of Fab’ and IgG-anti-CD22 immunotoxins in disseminated human B lymphomas grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res. 51: 5876–5880.

    PubMed  CAS  Google Scholar 

  29. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. (1992) The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD 19 immunotoxin. Blood 80: 2315–2320.

    PubMed  CAS  Google Scholar 

  30. Ghetie M-A, Tucker K, Richardson J, Uhr JW, Vitetta ES. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84: 702–707.

    PubMed  CAS  Google Scholar 

  31. Ghetie MA, Podar EM, Gordon BE, Pantazis P, Uhr JW, Vitetta ES. (1996) Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer 67: 1–4.

    Article  Google Scholar 

  32. Shah SA, Halloran PM, Ferris CA, et al. (1993) Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 53: 1360–1367.

    PubMed  CAS  Google Scholar 

  33. O’Connor R, Liu C, Ferris CA, et al. (1995) Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 86: 4286–4294.

    PubMed  Google Scholar 

  34. Uckun FM, Finnegan D, Gunther R, et al. (1994) In vivo efficacy of B-43 (anti-CD 19)-pokeweed antiviral protein (PAP) immunotoxin against BCL-1 murine B-cell leukemia. Blood 84: 702–707.

    Google Scholar 

  35. Uckun FM, Chelstrom LM, Finnegan D, et al. (1993) Effective immunochemotherapy of CALLA+C/x+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 79: 3116–3129.

    Google Scholar 

  36. FlaveU DJ, Flavell SU, Boehm DA, et al. (1995) Preclinical studies with the anti-CD 19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br. J. Cancer 72: 1373–1379.

    Article  Google Scholar 

  37. Vitetta ES, Stone M, Amlot P, et al. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51: 4052–4058.

    PubMed  CAS  Google Scholar 

  38. Amlot PL, Stone MJ, Cunningham D, et al. (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82: 2624–2633.

    PubMed  CAS  Google Scholar 

  39. Sausville EA, Headlee D, Stetler-Stevenson M, et al. (1995) Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85: 3457–3465.

    PubMed  CAS  Google Scholar 

  40. Stone MJ, Sausville EA, Fay JW, et al. (1996) A Phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88: 1188–1197.

    PubMed  CAS  Google Scholar 

  41. Conry RM, Khazaeli MB, Saleh MN, et al. (1995) Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin’s lymphoma: Effect of an intensive schedule of administration. J. Immunother. 18: 231–241.

    Article  CAS  Google Scholar 

  42. Kwak LW, Grossbard ML, Urba WJ. (1995) Clinical applications of monoclonal antibodies in cancer. In: De Vita VT, Jr, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer, J.B. Lippincott, Philadelphia, pp. 553–565.

    Google Scholar 

  43. Uckun FM. (1995) B43-pokeweed antiviral protein (B43-PAP) immunotoxin [abstract]. Fourth International Symposium on Immunotoxins, Myrtle Beach, S. Carolina, p. 162.

Download references

Acknowledgments

This work was supported by grants from the National Institutes of Health (CA28149), the Texas Higher Education Coordinating Board (003644-150), and The Meadows Foundation.

Author information

Authors and Affiliations

  1. Cancer Immunobiology Center and Department of Microbiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas, 75235-8576, USA

    Maria-Ana Ghetie, Victor Ghetie &  Ellen S. Vitetta

Authors
  1. Maria-Ana Ghetie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor Ghetie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ellen S. Vitetta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellen S. Vitetta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghetie, MA., Ghetie, V. & Vitetta, E.S. Immunotoxins for the Treatment of B-Cell Lymphomas. Mol Med 3, 420–427 (1997). https://doi.org/10.1007/BF03401689

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03401689

Keywords

Search

Navigation